NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Purpose Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300mg), and palonosetron (PALO 0.50 mg), a pharmacologically disti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Formato:	Artículo
Lenguaje:	English
Publicado:	2017
Materias:	RC Medicina Interna, Psiquiatría, Neurología
Acceso en línea:	http://eprints.uanl.mx/14551/1/63.pdf

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Ejemplares similares